RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature-Reference-Cited by-同舟云学术

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

Published:2020-05-20 Issue:2 Volume:8 Page:333-339
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Baglivo Sara,Ludovini Vienna,Moretti Riccardo,Bellezza Guido,Sidoni Angelo,Roila Fausto,Metro Giulio

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s40487-020-00116-2.pdf

Reference14 articles.

1. Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 2019;10:230.

2. Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol. 2020;38:1209–21.

3. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37:abstract 9008.

4. Drilon A, Oxnard G, Wirth L, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. J Thorac Oncol. 2019;14:abstract S6–S7.

5. Metro G, Di Maio M. Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? Transl Lung Cancer Res. 2018;7(Suppl 3):S294–S296296.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data;BMC Cancer;2024-02-05

2. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib;Critical Reviews in Oncology/Hematology;2024-02

3. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion;Journal of Thoracic Oncology;2023-05

4. Non-small-cell lung cancer: how to manage RET-positive disease;Drugs in Context;2022-07-11

5. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas;Expert Review of Anticancer Therapy;2022-06-27